LONDON–(BUSINESS WIRE) April 08, 2019 –ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the…Original Article
FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection
